PHARMACOGENICS APPROACH TO THE TREATMENT AND MANAGEMENT OF OVARIAN CANCER.
PURPOSE:
Many different drugs are available for cancer patients. Some of these drugs work better than others. Scientists believe that differences among patients may explain why some drugs work on some people and others do not. It is thought that these differences might best be explained by differences in genetic makeup among people.
In other words, the genes that make us who we are -- determine height, eye color and other traits -- might also explain how different people respond to different medical treatments.
The purpose of this project is to study the genes that might be involved when your body processes the various cancer medicines you were or are being treated with.
In other words, by studying your genes we hope to learn how they cause your body to respond to the chemotherapy you are receiving or have received.
With this improved understanding, we hope to be able in the future to design drugs that will be most appropriate for specific patients. That is, we hope that in the future we will be able to use patients' genetic makeup to provide medicines that are customized or targeted toward their particular needs.
PROCEDURES:
If you decide to participate in this study, a laboratory technician will draw 2 extra tablespoons of blood while blood is being taken as part of regular testing. (You will not be stuck with a needle any more than is already required for treatment and related testing.) If tissue is available from your surgery, a small sample will be collected for this study. No extra tissue will be removed for the purpose of this study. These samples will be used to prepare your genetic material for the test.
If you are interested in participating in this study, click on the link below to request an appointment. Be sure to include the name of the study in the “Reason for Appointment” field. REQUEST AN APPOINTMENT
A PHASE II TRIAL OF THALOMID IN COMBINATION WITH TAXOL AND CARBOPLATIN AS FIRST LINE THERAPY FOR ADVANCED STAGE (III AND IV) SUBOPTIMALLY DEBULKED PATIENTS WITH HISTOLOGIC PROVEN EPITHELIAL OVARIAN CANCER
PRINCIPAL INVESTIGATOR: Ramin Mirhashemi, M.D.
PATIENT INFORMATION (GENERAL)
You are being asked to participate in a clinical research study. You have the option not to participate. Please take your time making your decision. You may discuss it with your family and friends. This study is being carried out under the sponsorship of Bristol-Myers Squibb, the pharmaceutical company which has developed Taxol and Carboplatin, and Celgene, the pharmaceutical company which has developed Thalomid (Thalidomide). In general the research carried out compares the effectiveness of different methods of treating cancer of the female genital organs. In this manner, the best treatment—whether old or new—can be established.
AI
